The 20-year survival rates are unknown for the majority of melanoma patients-those with thin melanomas. We determined 20-year survival rates of patients diagnosed with thin melanomas (Յ 1.00 mm) in the general population and also determined the main prognostic factors.
INTRODUCTION
The incidence of cutaneous melanoma has continued to increase in populations worldwide, 1 with the most notable increases in in situ melanomas.
2, 3 Invasive melanoma has also continued to increase, although the majority of patients diagnosed since the 1980s have thin tumors (Breslow thickness Յ 1 mm). 4, 5 Basic clinical features at presentation that tend to reduce a person's survival from primary cutaneous melanoma are male sex, older age, and primary tumor site of the head, neck, trunk, palms, soles, or nail bed rather than limbs, 6 and those with metastases in regional lymph nodes at presentation have the worst prognosis. 7 Most prognostic details are derived from selected clinical populations. In combined clinical cohorts of patients who have been referred to major medical centers, specialist cancer centers, or cancer cooperative groups for their management, histologic factors-thickness of the primary tumor and the presence or absence of ulceration or mitoses-have been shown to independently influence survival. 8, 9 The specific survival rates and determinants for the majority of today's melanoma patients, those with thin melanomas, have been relatively little studied, with even fewer data available that are representative of patients with thin melanoma within entire populations. To date, the largest populationbased data set used to estimate medium-term survival of people diagnosed with thin melanomas is the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program in the United States: follow-up data for 19,734 patients with thin primary invasive melanomas of the skin and no evidence of metastasis who were diagnosed from 1988 to 1997 had a 15-year survival of 96%. 10 In an earlier, more detailed analysis of SEER data from 1988 to 2001, the 10-year survival rates for thin
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invasive melanomas ranged from 99% among the subgroup (n ϭ 10,648) who were younger than age 60 years with nonulcerated level II lesions to 70% among the rare subgroup (n ϭ 119) with thin, ulcerated level IV to V lesions. 5 Meanwhile, the 2009 American Joint Committee on Cancer (AJCC) staging of melanoma 8 based prognostic factors for thin melanoma on 11,841 clinic-based patients who had a generally poorer overall 10-year survival of 92%.
At this time, the only published Australian population-based data regarding long-term survival come from the New South Wales Cancer Registry. Among 18, 088 people diagnosed with a single thin invasive cutaneous melanoma between 1993 and 1998, the 10-year survival was 96% and the 15-year survival was 95%.
11 By comparison, the Sydney Melanoma Unit, a tertiary hospital referral center, reported 93% of 2,746 patients with thin melanomas diagnosed from 1979 to 1998 to be alive at 10 years and the 15-year survival was 89%. Patients from the Sydney Melanoma Unit were significantly younger than patients from the general population, and their melanomas were significantly thicker.
11
Since 1982, the reporting of cancer in Queensland, Australia, has been compulsory under legislation, and since that time, pathologists, hospitals, and nursing homes have provided data regarding all newly diagnosed melanomas in Queensland to the Queensland Cancer Registry (QCR). The QCR also obtains data about all deaths in the Queensland population, and thus it provides a resource from which we were able to assess long-term survival of all patients in the population diagnosed with thin melanomas (Յ 1.00 mm). We also studied the influence on prognosis of sex, age, tumor site, and standard histologic features that were available to us.
PATIENTS AND METHODS
Data obtained from the QCR for all patients in Queensland with a histologic diagnosis of an invasive melanoma from 1982 to 2006 were the basis of this study. These data were aggregated and nonidentifiable but written approval was obtained by the QCR from the data custodian, Queensland Health, before the data were released. Available clinical data for each person included sex, age at diagnosis, date of diagnosis, and anatomic site of the melanoma. Available pathology data comprised tumor thickness, level of invasion, and tumor morphology. Ulceration was not recorded during the period of this study, nor was information available about the presence of mitoses.
Since full anatomic subsite information was available for most people only from 1990, anatomic site was specified according to the fourth digit of the International Classification of Diseases (ICD) site codes. Melanomas on the "Face" comprised Lip (C44.0), Eyelid (C44.1), External ear (C44.2), and Other face (C44.3); other categories were Scalp and Neck (C44.4), Trunk (C44.5), Arm and Shoulder (C44.6), Leg and Hip (C44.7), and unknown or not otherwise specified (C44.9).
QCR data were matched against death registration data from the Queensland Registrar of Births, Deaths, and Marriages to identify the deaths of any people diagnosed with melanoma in Queensland who died in Queensland. People who were diagnosed with melanoma in Queensland but who died in another state or territory were identified by matching to the National Death Index at the Australian Institute of Health and Welfare. Cause of death was coded by using all available information: death certificates, autopsy reports, and pathology reports.
Melanoma-specific survival estimates were calculated on the basis of melanomas diagnosed between 1982 and 2006 (inclusive), with follow-up for all cases to December 31, 2007, allowing a minimum of 1 year's follow-up. Any patients who died from conditions other than melanoma before December 31, 2007, were censored at date of death, and those not known to have died were censored at December 31, 2007. Since there is evidence that survival outcomes differ between children diagnosed with melanomas and adults diagnosed with melanomas 12 and there is greater imprecision in cause of death coding among the oldest of the elderly, 13 we included only patients age 15 to 89 years at diagnosis.
Cause-specific survival estimates after 5, 10, 15, and 20 years of follow-up were generated by using the actuarial or life table method with 1-month intervals. Subgroup differences in survival were assessed by using Cox proportional hazards regression. Multivariate Cox proportional hazard models were also fitted. Checks of the proportional hazards assumption were made by using scaled Schoenfeld residuals testing for nonzero slope over time. Time-varying covariates were included in the regression model when there was evidence of significant violation (P Ͻ .05) of the proportional hazards assumption. The significance of each variable was assessed by comparing the difference in likelihood ratios and df for the model with and without the specific variable. Statistical significance was indicated by P Ͻ .05.
RESULTS
A total of 44,031 patients with invasive melanoma were registered at the QCR between 1982 and 2006. Of these, 3,029 patients (6.9%) with more than one invasive primary melanoma were removed from analysis since it was not possible to ascertain which melanoma determined the patient's survival. Of the remaining 41,002 patients, 2,881 (7.0%) had no information about tumor thickness and were excluded, along with 11,072 (27.0%) who had tumor thickness of more than 1.00 mm. A total of 27,049 remaining patients (66%) had been diagnosed with a thin (Յ 1.00 mm) invasive melanoma. Melanomas diagnosed by means other than histology (eg, cytology, clinical diagnosis, autopsy, or death certificate only) or by excision of a secondary melanoma with unknown primary were also excluded (0.4%; n ϭ 101) along with those age younger than 15 (0.4%; n ϭ 97) and those age Ն 90 years (0.4%; n ϭ 115) at diagnosis. Therefore, included in this analysis were 26,736 people diagnosed between 1982 and 2006 in the Queensland population with a histologically confirmed single primary invasive cutaneous melanoma Յ 1.00 mm thick. Their average age was 52.7 years (median, 53 years; range, 15 to 89 years), with an average age of 54.9 years among males and 50.2 years among females. Male-tofemale incidence ratio was 1.2:1. By December 31, 2007, 4,455 (17%) had died, of whom 592 (2.2% of the cohort) died from melanoma.
The overall 5-and 10-year melanoma-specific survival rates to 2007 for Queensland residents age 15 to 89 years when diagnosed with thin melanoma since 1982 were 98.7% and 97.4%, respectively. At 15 years and 20 years after diagnosis, respective melanoma-specific survival rates were 96.7% and 96.0%, with no significant (P ϭ .23) variation according to period of diagnosis (Table 1) . Females had a better survival than males overall (P Ͻ .001) and up to 10 years when survival rates were 98.5% (females) versus 96.5% (males). In general, survival decreased with increasing age such that melanomaspecific survival at 10 years or more among people age 65 to 89 years when diagnosed with thin melanoma was below 96.1% (Table 1) . People with melanoma occurring on the head and neck had generally lower long-term survival than those with melanoma on the trunk and limbs. With regard to histologic parameters, level of invasion of the dermis beyond the upper papillary dermis was associated with reduced long-term survival as were thickness Ն 0.75 mm and having tumors of the acral lentiginous or nodular subtypes (Table 1) .
When the independent effect of these patient and tumor characteristics on patient survival were estimated in a multivariate regression model, simultaneously adjusting for the effects of all other characteristics, results showed that people with a tumor thickness Ն 0.75 mm were more than four times more likely to die than those with very thin tumors (Ͻ 0.25 mm; adjusted hazard ratio [HR], 4.33; 95% CI, 2.8 to 6.8), including after 15 years of follow-up (18 deaths). Regardless of thickness, compared with people age 15 to 24 years, those older than age 45 years were also at increased risk of death from thin melanomas (Table 2) , with highest risk among those older than age 65 years (HR, 2.84; 95% CI, 1.8 to 4.5). Patients with tumors on the scalp or neck had a poorer outcome (HR, 1.68; 95% CI, 1.2 to 2.3) compared with those who had melanomas on the trunk; those with acral lentiginous melanomas had a poorer outcome (HR, 5.19; 95% CI, 2.3 to 11.8) compared with those who had superficial spreading melanoma and also nodular melanomas (NMs; HR, 1.80; 95% CI, 1.3 to 2.6), the latter causing a disproportionate number of deaths occurring 15 years after diagnosis (superficial spreading melanoma: 0.7%, 28 deaths among 4,178 eligible patients; NM: 5.8%, five deaths among 86 eligible patients). Patients with melanomas that filled the papillary dermis (level III) had a poorer outcome (HR, 1.74; 95% CI, 1.4 to 2.1) than those with invasion limited to the upper papillary dermis (level II; Table 2 ). 
DISCUSSION
Since most of today's patients with melanoma are diagnosed with thin (Յ 1.00 mm) primary melanomas, it is essential that information on their prognosis is up-to-date, accurate, and widely available, especially for younger patients. High-quality population-based data provide the soundest basis for reassurance to such patients that their risk of dying is small. This information also helps physicians best manage the majority of their patients whose survival is unlikely to be affected by their melanoma, while distinguishing the small proportion at relatively high risk of dying from their thin melanoma who may benefit from more aggressive treatments and long-term follow-up regimens. With more than 20 years of follow-up data for a cohort of 26,736 people in the Australian state of Queensland diagnosed with thin melanomas, we show that the long-term survival is 96%. These are the longest-term survival figures available for such people. Their value is enhanced by the fact that the estimates are based on the total experience of all patients with single thin primary melanomas diagnosed in this Abbreviations: HR, hazard ratio; NOS, not otherwise specified. *HRs are adjusted for all the other variables in the table. †The sex difference varied by time after diagnosis; for this reason interaction terms were included in the model. ‡Includes Ͻ five patients with "Into subcutis fat" morphology because of very small numbers.
entire population since 1982. Survival estimates from subsets of patients treated at selected treatment centers are systematically more pessimistic and therefore potentially misleading about the general outlook for these patients. This is highlighted by our population-based 97% overall 10-year survival, which is substantially better and likely more representative than the 92% reported by the 2009 AJCC staging of melanoma 8 which represents an amalgam of clinic-based patients. The medium-term survival estimates that are available for a few entire populations provide more valid comparisons. For example, people diagnosed with thin melanomas in the SEER program (1988 through 2006) had an average 15-year survival of 96%, similar to Australian estimates of 95% for the New South Wales population 11 and our 97% 15-year survival in Queensland.
The major feature that independently has the most severe detrimental effect on overall long-term survival from thin invasive melanoma is tumor thickness Ն 0.75 mm, which in the Queensland patient population carried a four-fold increase in mortality compared with patients who had the thinnest lesions (Ͻ 0.25 mm). The next most influential factor determining survival up to 20 years was a diagnosis of NM, which continued to be disproportionately associated with ongoing deaths after 15 years. Also influential in determining survival is patient age: patients older than age 65 years with thin melanomas had an almost three-fold increase in risk of dying from their melanoma when all other prognostic factors were taken into account. Beyond these factors, acral lentiginous melanomas, tumor thickness of 0.50 to 0.74 mm, male sex, tumor site on the scalp or neck, or tumor invasion of the entire papillary dermis all independently and significantly increase the risk of dying. These long-term data extend the evidence that has been available to date from medium-term follow-up of both population-based 11 and clinic-based 8,10,14,15 series. Although the results largely confirm that factors that predict medium-term survival also predict long-term survival, it has not been shown previously that the long-term outcome appears as poor for patients with level III as for level IV melanoma. From previous series examining prognosis in relation to anatomic site of cutaneous melanoma overall, it is known that patients with scalp and neck melanomas (registered together as a single ICD anatomic site code until 1990) have a worse prognosis when compared with those who have tumors at other sites. 5, 16, 17 We have now shown that melanomas on these sites have a detectable detrimental effect on prognosis, even in this group of patients with thin melanomas who have a generally better prognosis, independent of other prognostic factors.
The data used to create the AJCC staging system reported in 2001 identified the histologic presence of level IV and/or ulceration as adverse prognostic features for melanomas Ͻ 1.0 mm.
18 More recently, the staging system for this group of patients has changed so that the presence of mitoses is more relevant than level as an adverse feature 8 on the basis of clinic-based patients rather than patients from the general population. Although ulceration has not always been found to be an independent prognostic variable, 19 it was shown to be prognostic in a population-based cohort study. 11 Histologic information related to ulceration and to mitosis was not available to us, but we believe that this has not materially affected the accuracy of our results in the prediction of long-term survival in all patients with thin melanoma. First, it is known that ulceration is not a major feature; rather, it is a rare event in this patient group (1.2% in SEER data 5 ). Thus, the lack of specific information on ulceration is unlikely to have materially affected our results, apart from the possibility that the influence of factors highly correlated with ulceration, such as nodular histologic subtype, may be overestimated. It is highly probable however that the 1% of patients in our cohort with ulceration were captured in the subgroup with tumors of 0.75 to 1.0 mm thickness, or in the nodular subgroup whose long-term outcome was independently worse than that for other subtypes, independent of tumor thickness, with 20-year survival of 84.9% compared with 96.4% for superficial spreading melanoma. There are no population-based data available for assessing the true prevalence of mitosis in melanomas according to lesion thickness, reflecting the highly specialized use of this measure. It has been observed that within referred clinical series, mitosis is usually absent or rare in thin melanomas 9 ; however, knowledge of mitosis status is likely to have even less bearing than the presence of ulceration on the outlook for these patients in the community at large, although an independent effect for either of these rare features cannot be ruled out entirely.
The value of our results is that they improve the ability of physicians to accurately counsel patients about their long-term outlook. Although there is a need to establish an optimal routine follow-up protocol for this group of patients, our findings show that there is a subgroup for whom more careful assessment may be warranted. It is conceded, however, that beyond wide excision of the primary lesion with a minimum margin of 1 cm, 20 there is no additional therapy that has clearly been shown to improve survival. This includes a lack of knowledge about possible additional benefit of sentinel node biopsy (this has been a rare procedure among patients with thin melanoma in Queensland; elective node dissection is not performed); consistent with this is the lack of change in the prognosis in patients with thin melanoma in Queensland over the last two decades.
In conclusion, we have confirmed that the outlook for patients with thin invasive melanoma is generally extremely positive, with only four patients in 100 dying of their disease. This is heartening for patients and doctors. Moreover these data provide even more solid justification for continuing efforts to improve early detection through clinical surveillance and public education, particularly among older people for whom both the risk of melanoma and the risk of dying from that melanoma are comparatively high. We have shown that, in general, the thinner cutaneous melanomas are when diagnosed, the better. The public health approach to reducing melanoma mortality aims to shift the thickness distribution among all incident melanomas in the community toward systematically thinner lesions, and this must remain a high priority if melanoma morbidity and death rates are to be controlled.
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